The Sage Group

Thrombus in Peripheral Artery Disease (PAD): Prevalence and Market. A Significant But Recently Neglected Problem

Although the presence of thrombus in the peripheral arterial circulation carries well-known clinical consequences, thrombus size and prevalence in peripheral lesions has not been widely studied.

This report estimates the U.S. prevalence of thrombus in both symptomatic and asymptomatic peripheral artery disease (PAD) patients for the 2015-2030 period. Symptomatic disease is defined and intermittent claudication (IC) or critical limb ischemic (CLI). The market for PAD thrombus treatments (interventional and/or pharmaceutical) is also estimated.

Thrombus prevalence estimates are based on the number of PAD patients and limbs calculated according to the Diabetes Method. The published literature on the presence, characteristics and size of thrombus in the lower limb arteries is reviewed. The percentage of symptomatic and asymptomatic PAD patients with thrombus is based on conclusions from this review.

The market for treatment of thrombus in PAD is based on our assumption regarding the percentage of patients diagnosed and treated. Market estimates for 2015-2030 include the interventional thrombus treatment market in symptomatic patients and limbs as well as treatment of patients and limbs by disease severity. The pharmaceutical market for thrombus risk factor modification therapies is estimated for those with symptomatic as well as asymptomatic PAD.

Price: $5,200

To Purchase: